These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 10123844)

  • 1. Roundtable discussion. Maximizing potential cost benefits of teicoplanin through appropriate usage.
    Rybak MJ; Allen R; Arnow P; Craven PC; Freeman R; Grüneberg RN; Korin J; Nightingale CH; Rubinstein E; Schaison GS
    Hosp Formul; 1993 Jan; 28 Suppl 1():62-8. PubMed ID: 10123844
    [No Abstract]   [Full Text] [Related]  

  • 2. Current treatment of gram-positive infections: focus on efficacy, safety, and cost minimalization analysis of teicoplanin.
    Crane VS; Garabedian-Ruffalo SM
    Hosp Formul; 1992 Dec; 27(12):1199-200, 1203-4, 1207-10. PubMed ID: 10122506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health economics assessment study of teicoplanin versus vancomycin in Gram-positive infections.
    Portolés A; Palau E; Puerro M; Vargas E; Picazo JJ
    Rev Esp Quimioter; 2006 Mar; 19(1):65-75. PubMed ID: 16688294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating bone and joint infections with teicoplanin: hospitalization vs outpatient cost issues.
    Craven PC
    Hosp Formul; 1993 Jan; 28 Suppl 1():41-5. PubMed ID: 10123838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost implications of home care on serious infections.
    Rubinstein E
    Hosp Formul; 1993 Jan; 28 Suppl 1():46-50. PubMed ID: 10123839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects.
    Nathwani D; Li JZ; Balan DA; Willke RJ; Rittenhouse BE; Mozaffari E; Tavakoli M; Tang T
    Int J Antimicrob Agents; 2004 Apr; 23(4):315-24. PubMed ID: 15081078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections.
    Wilcox M; Nathwani D; Dryden M
    J Antimicrob Chemother; 2004 Feb; 53(2):335-44. PubMed ID: 14729745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-inpatient use of teicoplanin.
    Nathwani D
    Int J Clin Pract; 1998; 52(8):577-81. PubMed ID: 10622058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vancomycin vs teicoplanin in the treatment of Gram-positive infections: a pharmacoeconomic analysis in a Turkish University Hospital.
    Sancar AA; Yegenoglu S; de Vries R; Postma MJ; Simsek N; Pechlivanoglou P; Unal S
    Pharm World Sci; 2008 Dec; 30(6):916-23. PubMed ID: 18803030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teicoplanin in the therapy of gram-positive infections: an open non-randomized study.
    De Lalla F; Rinaldi E; Santoro D; Rizzardini G; Martello P; Guaglianone MH
    J Chemother; 1989 Jul; 1(4 Suppl):719-21. PubMed ID: 16312606
    [No Abstract]   [Full Text] [Related]  

  • 11. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.
    Cepeda JA; Whitehouse T; Cooper B; Hails J; Jones K; Kwaku F; Taylor L; Hayman S; Shaw S; Kibbler C; Shulman R; Singer M; Wilson AP
    J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
    Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
    Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Vancomycin and teicoplanin use as antibiotic prophylaxis in cardiac surgery: pharmacoeconomic study].
    Codina C; Miró JM; Tuset M; Claramonte J; Gomar C; Gotsens R; Gómez B; Suárez S; Abellana R; Ascaso C; Cartaña R; Rodríguez E; Asenjo M; Carné X; Trilla A; Marco F; Gómez J; Brunet M; Pomar JL; Gatell JM; Ribas J
    Med Clin (Barc); 2000; 114 Suppl 3():54-61. PubMed ID: 10994565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roundtable discussion. Cost justification of innovative drugs through assessment of total health care costs.
    Rybak MJ; Allen R; Craven PC; Freeman R; Nightingale CH; Normand C; Rubinstein E; Schaison GS; Whitelaw G
    Hosp Formul; 1993 Jan; 28 Suppl 1():33-6. PubMed ID: 10123836
    [No Abstract]   [Full Text] [Related]  

  • 15. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.
    Zhanel GG; Trapp S; Gin AS; DeCorby M; Lagacé-Wiens PR; Rubinstein E; Hoban DJ; Karlowsky JA
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):67-81. PubMed ID: 18251665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of teicoplanin in the ambulatory treatment of infections in children due to gram-positive microorganisms].
    Debbag R; Paganini H; Gómez S; Casimir L; Stamboulian D
    Medicina (B Aires); 2002; 62 Suppl 2():48-51. PubMed ID: 12481489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro susceptibility of Gram-positive pathogens to linezolid and teicoplanin and effect on outcome in critically ill patients.
    Wilson AP; Cepeda JA; Hayman S; Whitehouse T; Singer M; Bellingan G
    J Antimicrob Chemother; 2006 Aug; 58(2):470-3. PubMed ID: 16735420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbiological profile of teicoplanin.
    Covelli I; Nani E
    J Chemother; 1991 Jan; 3 Suppl 1():39-42. PubMed ID: 12041783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis.
    Brink AJ; Richards GA; Cummins RR; Lambson J;
    Int J Antimicrob Agents; 2008 Nov; 32(5):455-8. PubMed ID: 18718742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections.
    Pea F; Viale P
    Expert Rev Anti Infect Ther; 2007 Apr; 5(2):255-70. PubMed ID: 17402840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.